Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02939326
Recruitment Status : Completed
First Posted : October 20, 2016
Results First Posted : February 15, 2019
Last Update Posted : February 15, 2019
Sponsor:
Information provided by (Responsible Party):
Bonti, Inc.

Brief Summary:
To evaluate the safety and efficacy of EB-001 compared to placebo in subjects with glabellar frown lines (GL).

Condition or disease Intervention/treatment Phase
Glabellar Frown Lines (GL) Drug: EB-001 injection Drug: Placebo injection Phase 2

Detailed Description:
This study of EB-001 to measure safety and efficacy in GL. Single doses of EB- 001 administered through IM injection into procerus at midline and the medial and lateral corrugators will be assessed in healthy subjects with glabellar frown lines.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
Study Start Date : December 2016
Actual Primary Completion Date : July 12, 2017
Actual Study Completion Date : July 12, 2017

Arm Intervention/treatment
Placebo Comparator: Placebo

Intervention: Drug: Placebo

Single Injection of placebo into five (5) 0.1 mL IM injections into glabellar area.

Drug: Placebo injection
Other Name: Placebo

Active Comparator: EB-001 Dose 1 (1X)

Intervention: Drug: EB-001

Single Injection of Low Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area

Drug: EB-001 injection
Other Name: Botulinun Toxin Type E

Active Comparator: EB-001 Dose 2 (3X)

Intervention: Drug: EB-001, 3X Dose 1

Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area

Drug: EB-001 injection
Other Name: Botulinun Toxin Type E

Active Comparator: EB-001 Dose 3 (9X)

Intervention: Drug: EB-001, 9X Dose 1

Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area

Drug: EB-001 injection
Other Name: Botulinun Toxin Type E

Active Comparator: EB-001 Dose 4 (12X)

Intervention: Drug: EB-001, 12X Dose 1

Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area

Drug: EB-001 injection
Other Name: Botulinun Toxin Type E

Active Comparator: EB-001 Dose 5 (16X)

Intervention: Drug: EB-001, 16X Dose 1

Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area

Drug: EB-001 injection
Other Name: Botulinun Toxin Type E

Active Comparator: EB-001 Dose 6 (21X)
Intervention: Drug: EB-001, 21X Dose 1 Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
Drug: EB-001 injection
Other Name: Botulinun Toxin Type E

Active Comparator: EB-001 Dose 7 (28X)

Intervention: Drug: EB-001, 28X Dose 1

Single Injection of Highest Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area

Drug: EB-001 injection
Other Name: Botulinun Toxin Type E




Primary Outcome Measures :
  1. Investigator's Assessment of GL Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS). [ Time Frame: After single injection treatment up to 42 days ]

    Subjects Achieving a 2 Grade Response At Maximum Frown On Any Study Day By Dose using the Facial Wrinkle Scale (FWS)

    The FWS is a four-point scale that indicates severity of GL as follows: 0 = none, 1 = mild, 2 = moderate, or 3 = severe.

    Each scale is a four-point photonumeric scale based on photographs incorporating each aspect to be evaluated in a stepwise manner.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Signed and dated IRB-approved informed consent form (ICF).
  2. Men or women between the ages of 18 and 60, inclusive.
  3. Subjects in good health as determined by medical history, physical and focused neurological examinations, clinical laboratory studies, electrocardiograms (ECGs), vital signs, and Investigator's judgement.
  4. Presence of bilaterally symmetrical GL of moderate to severe rating at maximum frown, as measured using FWS by both the Investigator and subject prior to study treatment.
  5. Subjects with sufficient visual acuity without the use of eyeglasses (contact lens use acceptable) to accurately assess their facial wrinkles as determined by Investigator's judgement.
  6. Women of child bearing potential must not be pregnant, lactating, or planning to become pregnant during the study.
  7. Women of non-childbearing potential must be either postmenopausal (at least 12 consecutive months of amenorrhea) or surgically sterile (e.g., tubal ligation, hysterectomy, etc.).
  8. Women of childbearing potential agreeing to use dual methods of contraception from the day of dosing until 3 months afterwards. Female subjects using oral contraception must have initiated treatment at least 2 months prior to the day of dosing.
  9. Male subjects with partner(s) of childbearing potential agreeing to use dual methods of contraception from the day of dosing until 3 months afterwards, and to no sperm donation from day of dosing until 3 months afterwards.
  10. Willing and able to complete protocol requirements and instructions, which include completion of all required visits.

Exclusion Criteria:

  1. Any condition that precludes a subject's ability to comply with study requirements, including completion of the study visits or inability to read, understand, and/or self-assess GL severity using FWS.
  2. Any uncontrolled systemic disease or other medical condition.
  3. Any medical condition that may put the subject at increased risk with exposure to botulinum toxin of any serotype, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.
  4. Current or previous botulinum toxin treatment of any serotype.
  5. Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study treatment).
  6. Known immunization or hypersensitivity to any botulinum toxin serotype.
  7. Known allergy or sensitivity to any of the components of the study treatments, or any materials used in the study procedures.
  8. Any of the following procedures or treatments occurring within the specified period prior to screening:

    • 3 months: Non-ablative resurfacing laser or light treatment, microdermabrasion, or superficial peels.
    • 6 months: Any facial cosmetic procedure with medium depth to deep facial chemical peels (e.g., trichloroacetic acid [TCA] and phenol), or mid facial or periorbital laser skin resurfacing.
    • 6 months: On topical retinoid therapy and/or topical hormone cream applied to the face, who have not been on a consistent dose regimen and are unable to maintain the same regimen for the study.
    • 12 months: Mid-facial or periorbital treatment with non-permanent soft tissue fillers.
    • 12 months: On oral retinoid therapy.
  9. Prior periorbital surgery, facial lift (full face or mid face), brow lift, or related procedures (e.g., eyelid [blepharoplasty] and/or eyebrow surgery).
  10. Prior mid face or periorbital treatment with permanent soft tissue fillers, synthetic implantation (e.g., Gore-Tex®), and/or autologous fat transplantation.
  11. Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin.
  12. The inability to substantially lessen facial rhytides (fixed lines) even by physically spreading them apart, as determined by the Investigator.
  13. Permanent make-up that would interfere with the assessment of facial wrinkles.
  14. Subjects who, in the Investigator's opinion, are unable or unwilling to maintain their standardized skin care regimen throughout the study period.
  15. Any eyebrow or eyelid ptosis at baseline as determined by the Investigator.
  16. Infection or skin disorder at the injection sites.
  17. History of facial nerve palsy.
  18. Recent history (within 6 months of screening) of alcohol or drug abuse based on the Investigator's judgement.
  19. Anticipated need for surgery or overnight hospitalization during the study. Current enrollment in an investigational drug or device study or participation in such a study within 30 days or 5 half-lives of the drug, whichever is longer, of entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02939326


Locations
Layout table for location information
United States, California
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States, 94538
Steve Yoelin, MD Medical Associates, INC.
Newport Beach, California, United States, 92663
Sponsors and Collaborators
Bonti, Inc.
Investigators
Layout table for investigator information
Study Director: Earvin Liang Bonti, Inc.
  Study Documents (Full-Text)

Documents provided by Bonti, Inc.:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bonti, Inc.
ClinicalTrials.gov Identifier: NCT02939326     History of Changes
Other Study ID Numbers: EB001-GL201
First Posted: October 20, 2016    Key Record Dates
Results First Posted: February 15, 2019
Last Update Posted: February 15, 2019
Last Verified: January 2019